After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawl

AstraZeneca and Roche recently decided to end a patent infringement fight around Ultomiris. Now, we know the price of the deal.

AstraZeneca’s Alexion will pay $775 million to Roche’s Chugai Pharmaceutical to resolve all patent disputes related to the C5 inhibitor, the two companies said Thursday.